Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
1.89 USD +1.61% Intraday chart for Inhibikase Therapeutics, Inc. +22.73% +48.82%
May. 21 HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating MT
May. 16 Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating
MT
Maxim Initiates Inhibikase Therapeutics With Buy Rating, Price Target is $8
MT
HC Wainwright Starts Inhibikase Therapeutics at Buy With $5 Price Target
MT
JonesTrading Downgrades Inhibikase Therapeutics to Hold From Buy
MT
INHIBIKASE THERAPEUTICS : JonesTrading Initiates Inhibikase Therapeutics at Buy Rating With $12 Price Target
MT
DJ Industrial : US Stocks Drop After Some FOMC Members Signal Earlier Rate Hikes
MT
Close Update: US Stocks Decline as Fed Projects Rate Hike Implementation in 2023
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKT Stock
  4. News Inhibikase Therapeutics, Inc.
  5. Analyst Reco.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW